Please assess the completion status of the following clinical trial:

Trial Title: A Study Evaluating the Efficacy and Safety of Pregabalin Against Frequent Muscle Cramp in Patients With Liver Cirrhosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: (should follow all conditions described below)~* Etiology : Liver cirrhosis patients of any etiology, whether viral or non-viral~* Occurrence of muscle cramp equal to or more than 2 times a week over the last month~Exclusion Criteria:~* Preexisting disease : Occlusive vascular disease, thyroid disease, peripheral neuropathy~* Drugs within 2 months : Digitalis, cimetidine, clofibrate, lithium, opiate, nifedipine, beta-agonist, beta-blocker, penicillamine, gabapentin, pregabalin, tricyclic anti-depressant, carbamazepine, phenytoin, quinidine, antispastic drugs, verapamil, vitamin E, branched chain amino acid, excessive alcohol consumption (male \>40 g/day, female \>20 g/day)~* Underlying disease : Renal impairment (Ccr \< 60 mL/min), neuromuscular disease (stroke, cerebral palsy, multiple sclerosis, Parkinson disease, progressive muscular dystrophy, epilepsy), suicidal attack, drug allergy, pregnancy, heart failure~* Liver status : Serious complications resulting from decompensated cirrhosis except ascites, such as portosystemic encephalopathy, acute variceal bleeding within the past 3 months from study entry~* central nervous system (CNS) or peripheral nervous system (PNS) or muscular disease, stroke, cerebral palsy, multiple sclerosis, Parkinson disease, progressive muscular dystrophy, epilepsy~* The previous episode of suicidal attack~* Drug hypersensitivity~* Subjects receiving antiepileptic drugs~* Patients manipulating machines or driving cars~* Pregnant women~* Subjects with congestive heart failure requiring medications~* Galactose-Lactose metabolic abnormality~* Refractory ascites to medical treatment

- Gender: ALL
- Minimum Age: None
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Pregabalin (Type: ACTIVE_COMPARATOR): 30 randomly allocated patients after a 4-week run-in period, who will take part in a 6-week treatment period with pregabalin.~Treatment period : 75 mg twice daily during the first 1 week as titration + 150mg twice daily for 4 weeks as standard dose period + 75mg twice a day for a week as tapering period.
- Placebo (Type: PLACEBO_COMPARATOR): 30 randomly allocated patients after a 4-week run-in period, who will take part in a 6-week treatment period with placebo.~Treatment period : 75 mg twice daily during the first 1 week as titration + 150mg twice daily for 4 weeks as standard dose period + 75mg twice a day for a week as tapering period.

Based on this trial design, predict the completion outcome and termination type (if applicable).